ORAL JANUS KINASES IN PATIENTS WITH REFRACTORY MODERATE TO SEVERE ECZEMA

Abstract

Background: AD (eczema) has a complicated etiology that includes Th2 polarization, which is related with the cytokines IL-
4, IL-5, and IL-13, as well as Th22, Th17, and Th1 cells in chronic lesions. Janus kinases suppress Th1, Th2, and Th17
cytokines by preferentially inhibiting JAK3 and JAK1 receptors.
Aim: The current research sought to investigate the safety and effectiveness of oral Janus kinases in patients with refractory
moderate to severe eczema.
Methods: The trial included 32 adult individuals over the age of 18 with moderate to severe eczema who had previously
received systemic medication but had not responded well. At baseline, quality of life scores with DLQI (Dermatology Life
Quality Index), severity scores with SCORAD (SCORing Eczema), EASI (eczema area and severity index), past treatment
history, and demographic data were collected. Blood tests at baseline include the interferon-gamma release assay for TB, lipid
profile, renal function test, liver function test, and complete blood count. Subjects were evaluated every month for six months
to determine any adverse events, DLQI, blood tests, and severity levels.